A multinational study led by researchers at Mayo Clinic Comprehensive Cancer Center has achieved a major advancement in understanding genetic alterations of the BRCA2 gene, a critical factor in hereditary cancer risk. Through comprehensive functional assessment of all possible variants within BRCA2’s key DNA-binding domain, the team successfully classified 91% of previously uncertain variants (VUS) in this gene region. This breakthrough significantly enhances genetic testing accuracy and enables healthcare providers to deliver more precise risk assessments and personalized treatment plans for carriers of these variants.
Innovative Methodology and Key Findings
Published in Nature, the study employed CRISPR-Cas9 gene editing technology to analyze the functional impact of nearly 7,000 BRCA2 variants. This systematic approach clearly distinguished between variants that increase cancer risk and those that do not. Dr. Fergus Couch, Mayo Clinic’s Zbigniew and Anna M. Scheller Professor of Medical Research, emphasized that this research represents a substantial leap in understanding BRCA2’s role in cancer susceptibility, resolving uncertainties that have long complicated patient counseling and clinical decision-making.
Clinical Implications for Patient Care
The findings have immediate practical applications for genetic testing laboratories and healthcare providers. Patients with previously identified VUS will now receive reclassification notices as testing laboratories incorporate these new findings into their reports and updates. This clarity will enable more informed decisions regarding cancer screening, preventive measures, and treatment strategies. Additionally, the improved classification will help identify patients who may benefit from targeted therapies like PARP inhibitors across various cancers including breast, ovarian, pancreatic, and prostate cancer.
Foundation for Future Research
According to Dr. Couch, the study creates a comprehensive catalog of all possible VUS in this critical BRCA2 region, providing a valuable resource for guiding clinical care. More importantly, this research establishes a foundation for future studies characterizing and classifying BRCA2 variants across diverse populations and cancer types, ultimately improving risk assessment for all individuals.
Collaborative Effort and Funding Support
The study involved collaboration with Ambry Genetics Inc., Duke University, H. Lee Moffitt Cancer Center, University of Pennsylvania, and several contributing studies from the CARRIERS Consortium. Research support came from the National Cancer Institute, Mayo Clinic Breast Cancer SPORE (P50 CA116201) and R35 Outstanding Investigator Program, Mayo Clinic Comprehensive Cancer Center, and the Breast Cancer Research Foundation.
Related topics:
